LogoLogoMSF Science Portal
  • My saved items
logo

© Médecins Sans Frontières

MSF Science Portal
About MSF Science Portal
About MSF
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use

v2.1.4829.produseast1

Journal Article > Short Report

Culture conversion at six months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Seung KJ, Khan PY, Franke MF, Ahmed SM, Aiylchiev S, Alam MS, Putri FA, Bastard M, Docteur W, Gottlieb G, Hewison CCH, Islam S, Khachatryan N, Kotrikadze T, Khan UT, Kumsa A, Lecca L, Tassew YM, Melikyan N, Naing YY, Oyewusi L, Rich ML, Wanjala S, Yedilbayev A, Huerga H, Mitnick CD, endTB Study Group
Abstract
Delamanid should be effective against highly resistant strains of Mycobacterium tuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months.
Countries
ArmeniaBangladeshBelarusEthiopiaGeorgiaHaitiIndonesiaKazakhstanKenyaNorth KoreaKyrgyzstanLesothoMyanmarPakistanPeruSouth AfricaViet Nam
Subject Area
antibiotic resistancetuberculosisantimicrobial resistance
DOI
10.1093/cid/ciz1084
Published Date
02-Nov-2019
PubMed ID
31676905
Languages
English
Journal
Clinical Infectious Diseases
Volume / Issue / Pages
Volume 71, Issue 2, Pages 415-418
Issue Date
02-Nov-2019
Dimensions Badge